arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

HARROW, INC.

HROW
$40.53 ▲ +0.64 (+1.60%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
29 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
36
Health
Weak
Bearish
auto_awesome

Analytical Summary

HARROW, INC. faces fundamental challenges with weakness in Debt to Equity. The fundamentals warrant careful consideration of downside risks.

Market Cap $1.5B
Dividend Yield
Revenue Growth 36.4%
Op. Margin 11.2%
ROIC 37.9%
FCF / Share $1.17
Trailing P/E
Price / Book 28.8x
FCF Yield 2.9%
Debt / Equity 4.77
info Valuation on last close. End-of-day price, Aug 7, 2026.

29-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$272.30M
↑ +36.4%
Net Income Profit after all expenses
$-5.14M
↑ +70.6%
Operating Margin Operating profit as % of sales
11.2%
↑ +153.6% 59th
FCF / Share Free cash flow per share
$1.17
↑ +275.1%
Long-Term Debt Long-term obligations
$250.00M
↓ -4.8%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)

Health Breakdown

Profitability
54
Returns
34
Financial Health
31
Cash Quality
2

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 29 years · 80 quarters